Alterity Therapeutics LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
Alterity Therapeutics Limited announced positive topline data from its Phase 2 clinical trials for ATH434 in Multiple System Atrophy, demonstrating significant slowing of disease progression and a favorable safety profile.
NASDAQ
Alterity Therapeutics' annual report reveals ongoing operating losses and a need for additional funding, raising substantial doubt about its ability to continue as a going concern.